tirzepatide eating disorder Disorders After GLP-1s? for Heart Failure; Soda Taxes and BMI GLP-1RAs and Obesity Associated with

Injection sites are chosen based on the indication: near the injury site for musculoskeletal applications, or at a standard subcutaneous site (abdomen, thigh, upper arm) for systemic and GI applications

In a 16-week trial, liraglutide was found to reduce the expressed desire for palatable taste properties, including sweet, fatty, salty, and savory flavors in individuals with obesity (Kadouh et al., 2020)

used off-label for weight management when appropriate

Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program

Rastgoo S, Fateh ST, Nikbaf-Shandiz M, Rasaei N, Aali Y, Zamani M, et al